Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath-1H Induction with Sirolimus vs CsA in Kidney Transplant
NCT00309270Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Feb 2003
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of alemtuzumab in kidney transplantation (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Phenotypic and functional profiles of peripheral blood mononuclear cells at 12 months. Started Feb 2003; status: completed.
02
Drugs
alemtuzumab
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT00309270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00309270.